ENTERA BIO LTD. Proceeds from Stock Options Exercised
ENTERA BIO LTD. (ENTX) reported Proceeds from Stock Options Exercised of $130.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-05-08
- ENTERA BIO LTD. proceeds from stock options exercised for the quarter ending 2026-03-31 was $130.00K.
- ENTERA BIO LTD. proceeds from stock options exercised for the quarter ending 2025-03-31 was $0.00.
- ENTERA BIO LTD. proceeds from stock options exercised for the quarter ending 2024-12-31 was $181.00K.
- ENTERA BIO LTD. proceeds from stock options exercised for the quarter ending 2024-09-30 was $13.00K.
- ENTERA BIO LTD. proceeds from stock options exercised for fiscal 2025 was $20.00K, a 97.33% decline from fiscal 2024.
- ENTERA BIO LTD. proceeds from stock options exercised for fiscal 2024 was $749.00K.
- ENTERA BIO LTD. proceeds from stock options exercised for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ENTERA BIO LTD. proceeds from stock options exercised for fiscal 2022 was $13.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-03-31 | $130.00K 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $20.00K 10-K · filed 2026-03-27 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-08 | $181.00K derived: sum of 2 quarters · filed 2026-05-08 | $194.00K derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $194.00K derived: sum of 2 quarters · filed 2026-03-27 | $749.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $568.00K 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $555.00K 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | |||
| 2022-12-31 | $13.00K 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |